Anticancer Effect of COX-2 Inhibitor DuP-697 Alone and in Combination with Tyrosine Kinase Inhibitor (E7080) on Colon Cancer Cell Lines

Basit Öğe Kaydı
dc.authoridAltun, Ahmet -- 0000-0003-2056-8683en_US
dc.contributor.authorAltun, Ahmet
dc.contributor.authorTurgut, Nergiz Hacer
dc.contributor.authorKaya, Tijen Temiz
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T09:57:57Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T09:57:57Z
dc.date.issued2014
dc.department[Altun, Ahmet -- Turgut, Nergiz Hacer -- Kaya, Tijen Temiz] Cumhuriyet Univ, Fac Med, Dept Pharmacol, Sivas, Turkeyen_US
dc.description.abstractColorectal cancer remains one of the most common types of cancer and a leading cause of cancer death worldwide. In this study, we aimed to investigate effects of DuP-697, an irreversible selective inhibitor of COX-2 on colorectal cancer cells alone and in combination with a promising new multi-targeted kinase inhibitor E7080. The HT29 colorectal cancer cell line was used. Real time cell analysis (xCELLigence system) was conducted to determine effects on colorectal cell proliferation, angiogenesis was assessed with a chorioallantoic membrane model and apoptosis was determined with annexin V staining. We found that DuP-697 alone exerted antiproliferative, antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. For the antiproliferative effect the half maximum inhibition concentration (IC50) was 4.28x10(-8) mol/L. Antiangiogenic scores were 1.2, 0.8 and 0.5 for 100, 10 and 1 nmol/L DuP-697 concentrations, respectively. We detected apoptosis in 52% of HT29 colorectal cancer cells after administration of 100 nmol/L DuP-697. Also in combination with the thyrosine kinase inhibitor E7080 strong antiproliferative, antiangiogenic and apoptotic effects on HT29 colorectal cancer cells were observed. This study indicates that DuP-697 may be a promising agent in the treatment of colorectal cancer. Additionally the increased effects observed in the combination with thyrosine kinase inhibitor give the possibility to use lower doses of DuP-697 and E7080 which can avoid and/or minimize side effects.en_US
dc.description.sponsorshipCumhuriyet University Scientific Research Project (CUBAP, Sivas, Turkey) [T-468]en_US
dc.description.sponsorshipThis study was supported by Cumhuriyet University Scientific Research Project T-468 (CUBAP, Sivas, Turkey).en_US
dc.identifier.doi10.7314/APJCP.2014.15.7.3113en_US
dc.identifier.endpage3121en_US
dc.identifier.issn1513-7368
dc.identifier.issue7en_US
dc.identifier.pmid24815456en_US
dc.identifier.scopus2-s2.0-84900839951en_US
dc.identifier.scopusqualityQ3
dc.identifier.startpage3113en_US
dc.identifier.urihttps://dx.doi.org/10.7314/APJCP.2014.15.7.3113
dc.identifier.urihttps://hdl.handle.net/20.500.12418/8409
dc.identifier.volume15en_US
dc.identifier.wosWOS:000336834500029en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherASIAN PACIFIC ORGANIZATION CANCER PREVENTIONen_US
dc.relation.ispartofASIAN PACIFIC JOURNAL OF CANCER PREVENTIONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectColon canceren_US
dc.subjectDuP-697en_US
dc.subjectCOX-2 inhibitionen_US
dc.subjecttyrosine kinase inhibitoren_US
dc.titleAnticancer Effect of COX-2 Inhibitor DuP-697 Alone and in Combination with Tyrosine Kinase Inhibitor (E7080) on Colon Cancer Cell Linesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu